Celcuity is developing the world’s first diagnostic tests that use a patient’s live tumor cells to identify the specific biological driver of their cancer. Our CELx Signaling Function technology represents a paradigm shift away from the genomic or proteomic based analyses used today to diagnose cancer. We leapfrog these traditional approaches by analyzing the functionality of the disease-related signaling pathways of a patient’s tumor cells in real-time. This more complete and accurate diagnostic approach enables us to identify cancer subtypes other technologies cannot detect. Our goal is to ensure patients receive the drug therapy that most precisely matches the biology of their cancer.